Baseline clinical characteristics of patients with prior pancreatitis tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
| Clinical variables | All prior pancreatitis | SARS-CoV-2 RNA | SARS-CoV-2-RNA | P value |
| Patients (n=102) | Negative (n=94) | Positive (n=8) | ||
| Demographics | ||||
| Age, years (SD) | 55.3 (±18.7) | 54.2 (±18.5) | 69.3 (±16.4) | 0.039 |
| Male gender, n (%) | 41 (40.2) | 35 (37.2) | 6 (75.0) | 0.036 |
| Asian ethnicity, n (%) | 11 (10.8) | 8 (8.5) | 3 (37.5) | 0.011 |
| History of pancreatitis | ||||
| Acute, total, n (%) | 87 (85.3) | 81 (86.2) | 6 (75.0) | 0.392 |
| Chronic, total, n (%) | 15 (14.7) | 13 (13.8) | 2 (25.0) | 0.334 |
| Aetiology of pancreatitis | ||||
| Idiopathic, n (%) | 43 (42.2) | 36 (38.3) | 7 (87.5) | 0.007 |
| Gallstone, n (%) | 30 (29.4) | 29 (30.9) | 1 (12.5) | 0.274 |
| Alcohol, n (%) | 13 (12.7) | 13 (13.8) | 0 (0.0) | 0.260 |
| Drug induced, n (%) | 7 (6.9) | 7 (7.4) | 0 (0.0) | 0.424 |
| Autoimmune, n (%) | 4 (3.9) | 4 (4.3) | 0 (0.0) | 0.552 |
| Hypertriglyceridaemia, n (%) | 1 (1.0) | 1 (1.1) | 0 (0.0) | 0.768 |
| Post-ERCP, n (%) | 3 (2.9) | 3 (3.2) | 0 (0.0) | 0.608 |
| Cystic fibrosis, n (%) | 2 (2.0) | 2 (2.1) | 0 (0.0) | 0.769 |
ERCP, endoscopic retrograde cholangiopancreatography.